Institut Paoli Calmettes Myelodysplastic Syndromes Database

Myelodysplastic Syndromes Clinical Trial

Official title:

Institut Paoli Calmettes Myelodysplastic Syndromes Database

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03275480
• Other study ID #: BDD-SMD-IPC
• Status: Recruiting
• Start date: January 18, 2016
• Est. completion date: December 2030

Study information

• Verified date: May 2019
• Source: Institut Paoli-Calmettes
• Contact: Dominique Genre, MD
• Phone: +33491223778
• Email: drci.up[@]ipc.unicancer.fr
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Database of Institut Paoli-Calmettes patients diagnosed with Myelodysplastic Syndromes

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 10000
• Est. completion date: December 2030
• Est. primary completion date: January 2030
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient with a diagnosis of Myelodysplastic Syndromes

Exclusion Criteria:

• None

Related Conditions & MeSH terms

• Myelodysplastic Syndromes
• Preleukemia
• Syndrome

Locations

Country	Name	City	State
France	Institut Paoli-Calmettes	Marseille	Paca

Sponsors (1)

Lead Sponsor	Collaborator
Institut Paoli-Calmettes

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Survival of patients with myelodysplastic syndrome(MDS)	Overall survival of all patients with MDS who are taken in charge in Institut Paoli Calmettes Cancer Center	10 years
Secondary	Collection of patients characteristics	Collection of characteristics of patients treated at Institut Paoli Calmettes in order to set up prospective and retrospective studies	10 years